Indiana University

Denodo Partners with Google Cloud on the Future of Enterprise Innovation with New Data Virtualization and Generative AI Integration

Retrieved on: 
Monday, April 8, 2024

GOOGLE CLOUD NEXT, Booth 1362 - Denodo , a leader in data management, announced a new integration of the Denodo Platform with Google Cloud’s Vertex AI as part of its partnership.

Key Points: 
  • GOOGLE CLOUD NEXT, Booth 1362 - Denodo , a leader in data management, announced a new integration of the Denodo Platform with Google Cloud’s Vertex AI as part of its partnership.
  • Powered by data virtualization , the Denodo Platform will work with Google Cloud to empower joint customers to drive innovative solutions by combining advanced logical data management capabilities with cutting-edge generative AI services while providing access to state-of-the-art large language models (LLM).
  • “Generative AI can significantly improve how businesses operate and benefit virtually every industry,” said Ritika Suri, Technology Partnerships director, at Google Cloud.
  • “This latest integration further sets the stage for enterprises to redefine the boundaries of innovation by unlocking new levels of business value through the power of data and generative AI.

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors

Retrieved on: 
Tuesday, April 9, 2024

TEMPE, Ariz., April 9, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).

Key Points: 
  • ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).
  • Patients enrolled in the ROADS clinical trial are randomized into two treatment groups following craniotomy with brain metastasis tumor removal: GammaTile implant at the time of surgery versus post-operative SRT.
  • Enrollment in the Phase 3 trial has now surpassed half of the 180 planned patients.
  • Our dedication to the ROADS trial is fueled by our mission to furnish the highest caliber of clinical evidence through randomized trial research.

Amish Patel Joins Sierra Space as Chief Operating Officer

Retrieved on: 
Thursday, March 28, 2024

Sierra Space , a leading commercial space-tech company and next generation defense-tech prime building a platform in space to benefit life on Earth and protect the freedom of economic activity in the Orbital Age®, is pleased to announce the appointment of Amish Patel as Chief Operating Officer.

Key Points: 
  • Sierra Space , a leading commercial space-tech company and next generation defense-tech prime building a platform in space to benefit life on Earth and protect the freedom of economic activity in the Orbital Age®, is pleased to announce the appointment of Amish Patel as Chief Operating Officer.
  • In his new role, Amish will oversee all aspects of the company’s operations, including purview over Sierra Space’s global supply chain and manufacturing.
  • View the full release here: https://www.businesswire.com/news/home/20240327862906/en/
    Amish Patel has joined Sierra Space as the company's Chief Operating Officer (PHOTO: SIERRA SPACE)
    With nearly two decades of extensive experience in supply chain and operations spanning various industries including aerospace and automotive, Amish brings a wealth of high-tech operational expertise to his new appointment.
  • “I am honored to join Sierra Space at such an exciting time in the aerospace industry,” said Amish Patel.

Demeetra and Indiana University Biopesticide Platform Combining Gene Editing and Synthetic Biology Selected as a MDPI Journal Editor’s Choice Article

Retrieved on: 
Wednesday, March 20, 2024

A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.

Key Points: 
  • A pioneering study, authored by scientists from Demeetra and Indiana University, has been selected for the MDPI Journals Editor's Choice Articles , highlighting the impact of advanced gene editing in synthetic biology to produce biopesticides.
  • View the full release here: https://www.businesswire.com/news/home/20240320823585/en/
    Demeetra and Indiana University research on gene edited yeast biopesticide was featured on the front cover of Fermentation.
  • According to MDPI “Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world.
  • “We wanted to engineer the ideal yeast platform for stable RNAi expression,” said Dr. Corey Brizzee, Director of Gene Editing at Demeetra.

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

B. Riley Expands Corporate Advisory and Valuation Services Practice with Key Hire

Retrieved on: 
Monday, March 25, 2024

LOS ANGELES, March 25, 2024 /PRNewswire/ -- B. Riley Financial (Nasdaq: RILY) today announced the addition of Virginia Schnippel as a Managing Director within the Corporate Advisory & Valuation Services practice at B. Riley Advisory Services.

Key Points: 
  • Virginia Schnippel joins as Managing Director with B. Riley Advisory Services in Chicago
    LOS ANGELES, March 25, 2024 /PRNewswire/ -- B. Riley Financial (Nasdaq: RILY) today announced the addition of Virginia Schnippel as a Managing Director within the Corporate Advisory & Valuation Services practice at B. Riley Advisory Services.
  • "We are excited to welcome Virginia and her skills to our corporate advisory valuation services team," said Chad Yutka, Executive Managing Director and National Corporate Advisory & Valuation Services Practice Leader at B. Riley Advisory Services.
  • "Virginia brings significant industry and valuation experience across many industries, and her addition demonstrates our commitment to having best-in-class expertise in advisory services offerings."
  • She joins B. Riley from CohnReznick where she most recently served as a Principal in the firm's Valuation Advisory Group.

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

DECISIONPOINT HIRES MATT BRINGMAN AS ITS NEW CHIEF GROWTH OFFICER

Retrieved on: 
Tuesday, March 12, 2024

GAITHERSBURG, Md., March 12, 2024 /PRNewswire/ -- DecisionPoint Corporation has hired Matt Bringman as its Chief Growth Officer.

Key Points: 
  • GAITHERSBURG, Md., March 12, 2024 /PRNewswire/ -- DecisionPoint Corporation has hired Matt Bringman as its Chief Growth Officer.
  • Matt will provide oversight to the business development, capture, and pricing teams within the Growth organization.
  • We will continue to build a culture of growth working together to unlock potential and continue on the path of success," said Matt.
  • "I believe Matt will enrich DecisionPoint with a wealth of innovative thinking, reinforced by his track record of demonstrated leadership, growth, and extensive management expertise.

During the 2024 eclipse, biologists like us want to find out how birds will respond to darkness in the middle of the day

Retrieved on: 
Friday, April 5, 2024

The total solar eclipse on April 8, 2024, coincides with an exciting time for wild birds.

Key Points: 
  • The total solar eclipse on April 8, 2024, coincides with an exciting time for wild birds.
  • Local birds are singing for mates and fighting for territories as they gear up for their once-a-year chance to breed.
  • Tens of millions of migrating birds will be passing through the path of totality, and they mostly migrate at night.

There’s an app for that


On average, a total solar eclipse occurs in the same place only once every 375 years. Most wild animals, like most people, have never seen the sky quickly switch to night in the middle of the day. These rare events are a natural experiment that can help scientists like us understand how animals respond to an unusual sudden change in light.

  • Observers have reported that zoo animals acted distressed or went into their enclosures.
  • With collaborators across our campus – including Jo Anne Tracey at the Office of Science Outreach and Paul Macklin at Indiana University’s Luddy School of Informatics, Computing, and Engineering – we have created an app called SolarBird.
  • The app asks participants to find a bird and watch it or listen to it for 30 seconds, while clicking a few prompts on what the bird does before, during and after totality.

Technology and bird behavior

  • For example, during the August 2017 solar eclipse, researchers collected data from weather stations across the United States, including several sites along the path of totality.
  • The team saw some changes in activity – mainly, the birds didn’t follow their typical daytime activity patterns as much, but they saw no consistent increase in night-like activity.
  • Because they used radar, it’s not clear exactly which bird behaviors increased or decreased.
  • Bird songs generally convey two critical messages: “keep away” to a rival and “come here” to a prospective mate.
  • Software advances help to automate the process of identifying bird songs by species with less work on the human end.
  • We started recording the last week of March to collect song rates at a typical dawn and a typical dusk.
  • For example, artificial light at night can affect bird physiology, behavior and abundance, and the total solar eclipse gives us a new way to test how light pollution affects behavior.


Kimberly Rosvall receives funding from the National Science Foundation. Liz Aguilar receives funding from the National Science Foundation and Indiana Space Grant Consortium.

Alivi Health Appoints Amanda Novak as Vice President of Business Development

Retrieved on: 
Tuesday, February 27, 2024

Alivi Health, a leading provider of transportation, card-based, and specialty benefits, is excited to announce the appointment of Amanda Novak as the newest addition to their team as Vice President of Business Development.

Key Points: 
  • Alivi Health, a leading provider of transportation, card-based, and specialty benefits, is excited to announce the appointment of Amanda Novak as the newest addition to their team as Vice President of Business Development.
  • With an impressive sales and business development background within the healthcare industry, Amanda brings a wealth of experience and expertise to the organization.
  • Before joining Alivi, Amanda was Vice President of Health Plan Sales with WEX, where she demonstrated exceptional leadership and strategic expertise.
  • Her track record includes spearheading successful initiatives and forging strong partnerships to drive business growth and revenue.